Clinical Trial Search

Primary: Splenic Response Rate at Week 24 — 57; 64; 158; 153 Participants — p=0.014

Primary: Number of Subjects With Adverse Events Ongoing From Parent Study at Start of Study NI-AC303) — 59; 62 Participants

Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg

Primary: ß-cell Response Measured by Hyperglycemic Clamp — 3.65; 3.58; 3.60; 3.73 nmol/L — p=>0.05

Primary: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence — 0.292; 0.402; 0.321; 0.444 millimeters (mm) — p=0.0072

Primary: Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. — 0; 0; 1; 0 Participants

Primary: Overall Survival (OS) — 18.7; 18.9 months — p=0.633

Primary: PBAC Scores — 292; 146 score on a scale

Primary: Number of Participants at Each Global Rank Endpoint Based Upon Their Most-severe Outcome — 12; 17; 3; 7 Participants — p=0.14

Primary: Number of Participants With Ocular Treatment Emergent Adverse Events — 16 Participants

Primary: Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68 — 92.6; 91.9…

Primary: Number of Participants With Complete Response — 13; 21; 33; 24 Participants

Primary: No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and…

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…